Literature DB >> 30807093

PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.

Christopher P Tinworth1,2, Hannah Lithgow1,2, Lars Dittus3, Zuni I Bassi1, Sophie E Hughes1, Marcel Muelbaier3, Han Dai4, Ian E D Smith1, William J Kerr2, Glenn A Burley2, Marcus Bantscheff3, John D Harling1.   

Abstract

The impact of covalent binding on PROTAC-mediated degradation of BTK was investigated through the preparation of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib. It was determined that a covalent binding PROTAC inhibited BTK degradation despite evidence of target engagement, while BTK degradation was observed with a reversible binding PROTAC. These observations were consistently found when PROTACs that were able to recruit either IAP or cereblon E3 ligases were employed. Proteomics analysis determined that the use of a covalently bound PROTAC did not result in the degradation of covalently bound targets, while degradation was observed for some reversibly bound targets. This observation highlights the importance of catalysis for successful PROTAC-mediated degradation and highlights a potential caveat for the use of covalent target binders in PROTAC design.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30807093     DOI: 10.1021/acschembio.8b01094

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  32 in total

1.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

Review 2.  Emerging modes-of-action in drug discovery.

Authors:  Eric Valeur; Frank Narjes; Christian Ottmann; Alleyn T Plowright
Journal:  Medchemcomm       Date:  2019-06-25       Impact factor: 3.597

Review 3.  Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.

Authors:  Tinghu Zhang; John M Hatcher; Mingxing Teng; Nathanael S Gray; Milka Kostic
Journal:  Cell Chem Biol       Date:  2019-10-17       Impact factor: 8.116

Review 4.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

5.  Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.

Authors:  Nan Bai; Sven A Miller; Grigorii V Andrianov; Max Yates; Palani Kirubakaran; John Karanicolas
Journal:  J Chem Inf Model       Date:  2021-02-24       Impact factor: 4.956

6.  Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.

Authors:  Yamit Shorer Arbel; Ben-Zion Katz; Ronen Gabizon; Amit Shraga; Yotam Bronstein; Talia Kamdjou; Anat Globerson Levin; Chava Perry; Irit Avivi; Nir London; Yair Herishanu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

7.  Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes.

Authors:  James Schiemer; Reto Horst; Yilin Meng; Justin I Montgomery; Yingrong Xu; Xidong Feng; Kris Borzilleri; Daniel P Uccello; Carolyn Leverett; Stephen Brown; Ye Che; Matthew F Brown; Matthew M Hayward; Adam M Gilbert; Mark C Noe; Matthew F Calabrese
Journal:  Nat Chem Biol       Date:  2020-11-16       Impact factor: 15.040

Review 8.  Trends in kinase drug discovery: targets, indications and inhibitor design.

Authors:  Misty M Attwood; Doriano Fabbro; Aleksandr V Sokolov; Stefan Knapp; Helgi B Schiöth
Journal:  Nat Rev Drug Discov       Date:  2021-08-05       Impact factor: 84.694

Review 9.  Targeting Protein Kinases Degradation by PROTACs.

Authors:  Fei Yu; Ming Cai; Liang Shao; Jihong Zhang
Journal:  Front Chem       Date:  2021-06-30       Impact factor: 5.221

10.  Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy.

Authors:  Minghua Yuan; Yanan Chu; Yongtao Duan
Journal:  Front Chem       Date:  2021-07-05       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.